Breast cancer cells
The multidisciplinary teams that lead the treatment of each patient with breast cancer at City of Hope are able to deliver complex, subspecialized care because of their individual expertise. While surgery is often only one part of treatment, we lead the way in innovative and thoughtful surgical approaches to treating breast cancer and strive to take a minimally invasive approach to reduce discomfort, hasten recovery time and allow for patients to proceed with postsurgical treatments sooner.
This world-class, multidisciplinary approach has led to our survival for breast cancer exceeding the SEER National average at all stages.*
*Data were derived from City of Hope cancer registry (CNeXT) and SEER November 2019 Research Data Files as the comparator. All City of Hope patients were diagnosed from 2007 through 2016, and the City of Hope follow-up cutoff date was 12/31/2017, to align with SEER data. Survival time was based on first occurring BCA diagnosis during the time period of interest.
City of Hope Female Breast Cancer Adjusted† Overall Survival vs SEER National (2007-2016)
â€ Proportional hazards regression survival estimates adjusting for age category (15-44, 45-54, 55-64, 65-74 and 75+), race (white, Black and other) and Stage (II/III/IV vs I).
City of Hope Stage IV survival is 50% greater than the SEER National average 10 years postdiagnosis
The adjusted survival probabilities for City of Hope female breast cancer patients across all Stages (I, II, III and IV) were compared to the SEER† National data three, five and 10 years after diagnosis. The percent difference after 10 years was ≥5% at all stages of cancer, with the largest differences seen in Stage IV patients regardless of year (3 yr: 21%; 5 yr: 31%; 10 yr: 50%).
You can find more information in our full Breast Outcome Report .
The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program
An authoritative source on cancer incidence and survival, the SEER Program provides cancer statistics to reduce the cancer burden among the U.S. population. It is supported by the Surveillance Research Program, which provides national leadership in cancer surveillance using analytical tools and methodological expertise in collecting, analyzing, interpreting and disseminating reliable population-based statistics.